JP2015525208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525208A5 JP2015525208A5 JP2015514144A JP2015514144A JP2015525208A5 JP 2015525208 A5 JP2015525208 A5 JP 2015525208A5 JP 2015514144 A JP2015514144 A JP 2015514144A JP 2015514144 A JP2015514144 A JP 2015514144A JP 2015525208 A5 JP2015525208 A5 JP 2015525208A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- isolated
- purified
- cancer
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650020P | 2012-05-22 | 2012-05-22 | |
| US61/650,020 | 2012-05-22 | ||
| PCT/US2013/042162 WO2013177247A1 (en) | 2012-05-22 | 2013-05-22 | Murine anti-ny-eso-1 t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018139890A Division JP2018196384A (ja) | 2012-05-22 | 2018-07-26 | マウス抗ｎｙ−ｅｓｏ−１ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525208A JP2015525208A (ja) | 2015-09-03 |
| JP2015525208A5 true JP2015525208A5 (enExample) | 2016-06-02 |
| JP6378172B2 JP6378172B2 (ja) | 2018-08-22 |
Family
ID=48539439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514144A Active JP6378172B2 (ja) | 2012-05-22 | 2013-05-22 | マウス抗ｎｙ−ｅｓｏ−１ｔ細胞受容体 |
| JP2018139890A Pending JP2018196384A (ja) | 2012-05-22 | 2018-07-26 | マウス抗ｎｙ−ｅｓｏ−１ ｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018139890A Pending JP2018196384A (ja) | 2012-05-22 | 2018-07-26 | マウス抗ｎｙ−ｅｓｏ−１ ｔ細胞受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9487573B2 (enExample) |
| EP (3) | EP3527584B8 (enExample) |
| JP (2) | JP6378172B2 (enExample) |
| CN (2) | CN107881183B (enExample) |
| AU (1) | AU2013266421B2 (enExample) |
| CA (1) | CA2874486C (enExample) |
| ES (3) | ES2835200T3 (enExample) |
| IL (1) | IL235720A0 (enExample) |
| PT (2) | PT3527584T (enExample) |
| WO (1) | WO2013177247A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013177247A1 (en) * | 2012-05-22 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Murine anti-ny-eso-1 t cell receptors |
| EP3653212B1 (en) | 2012-12-20 | 2023-04-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| WO2015113140A1 (en) * | 2014-01-29 | 2015-08-06 | University Health Network | Methods and compositions for producing a cell expressing a t cell receptor |
| AU2015339743C1 (en) | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| EP3067366A1 (en) * | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| AU2016283133A1 (en) * | 2015-06-24 | 2018-01-04 | Eureka Therapeutics, Inc. | Constructs targeting NY-ESO-1 peptide/MHC complexes and uses thereof |
| IL295616A (en) * | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| CN106632660B (zh) * | 2015-11-04 | 2021-01-29 | 广东香雪精准医疗技术有限公司 | 识别ny-eso-1抗原短肽的tcr |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| EP3568412A2 (en) * | 2017-01-13 | 2019-11-20 | Agenus Inc. | T cell receptors that bind to ny-eso-1 and methods of use thereof |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| EP3579877A4 (en) * | 2017-02-09 | 2020-12-09 | The Regents of The University of California | CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| US10386882B2 (en) * | 2017-04-14 | 2019-08-20 | Allegro Microsystems, Llc | Control circuit |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| CA3070468A1 (en) | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| US20200316122A1 (en) | 2017-10-11 | 2020-10-08 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using p38 mapk inhibitors |
| AU2019209428B2 (en) | 2018-01-22 | 2025-06-26 | Endocyte, Inc. | Methods of use for CAR T cells |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| ES3052818T3 (en) | 2018-02-09 | 2026-01-14 | Us Health | Tethered interleukin-15 and interleukin-21 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| WO2019162043A1 (en) * | 2018-02-26 | 2019-08-29 | Medigene Immunotherapies Gmbh | Nyeso tcr |
| EP3784774B1 (en) | 2018-04-24 | 2025-11-19 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
| CN110856751B (zh) | 2018-08-24 | 2024-12-03 | 杭州康万达医药科技有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
| CA3111381A1 (en) * | 2018-09-05 | 2020-04-30 | The Regents Of The University Of California | Composition of ny-eso-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules |
| EA202191107A1 (ru) * | 2018-10-23 | 2021-09-17 | Ридженерон Фармасьютикалз, Инк. | T-клеточные рецепторы ny-eso-1 и способы их применения |
| US12448429B2 (en) | 2019-03-06 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| EP4100428A4 (en) | 2020-02-04 | 2024-03-06 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2022055946A1 (en) | 2020-09-08 | 2022-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| CN112375136B (zh) * | 2020-11-03 | 2022-06-07 | 中国科学院微生物研究所 | Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途 |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| EP4456911A2 (en) | 2021-12-31 | 2024-11-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell therapy with vaccination as a combination immunotherapy against cancer |
| WO2025077869A1 (en) * | 2023-10-13 | 2025-04-17 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ny-eso-1 antibodies and uses thereof |
| WO2025160480A1 (en) | 2024-01-26 | 2025-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| EP1019439B1 (en) * | 1997-10-02 | 2011-11-16 | Altor BioScience Corporation | Soluble single-chain t-cell receptor proteins |
| CN1269412A (zh) * | 2000-03-17 | 2000-10-11 | 国家人类基因组南方研究中心 | 一种新的人t细胞受体相关蛋白及其编码序列 |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| EP1421115B1 (en) | 2001-08-31 | 2005-03-02 | Avidex Limited | Soluble t cell receptor |
| JP4773434B2 (ja) | 2004-05-19 | 2011-09-14 | イムノコア リミテッド | 高親和性ｎｙ−ｅｓｏｔ細胞受容体 |
| US7915036B2 (en) | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| MX2009009926A (es) * | 2007-03-13 | 2010-03-15 | Univ Zuerich | Anticuerpo tumor-especifico humano monoclonal. |
| AU2008304555A1 (en) | 2007-09-25 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
| BR112013006718B1 (pt) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| WO2013177247A1 (en) * | 2012-05-22 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Murine anti-ny-eso-1 t cell receptors |
-
2013
- 2013-05-22 WO PCT/US2013/042162 patent/WO2013177247A1/en not_active Ceased
- 2013-05-22 ES ES19152955T patent/ES2835200T3/es active Active
- 2013-05-22 ES ES20201340T patent/ES2998514T3/es active Active
- 2013-05-22 PT PT191529551T patent/PT3527584T/pt unknown
- 2013-05-22 PT PT13726389T patent/PT2852613T/pt unknown
- 2013-05-22 AU AU2013266421A patent/AU2013266421B2/en active Active
- 2013-05-22 ES ES13726389T patent/ES2718474T3/es active Active
- 2013-05-22 EP EP19152955.1A patent/EP3527584B8/en active Active
- 2013-05-22 CN CN201711136635.4A patent/CN107881183B/zh active Active
- 2013-05-22 EP EP20201340.5A patent/EP3828197B1/en active Active
- 2013-05-22 US US14/401,893 patent/US9487573B2/en active Active
- 2013-05-22 CN CN201380038884.3A patent/CN104507963B/zh active Active
- 2013-05-22 CA CA2874486A patent/CA2874486C/en active Active
- 2013-05-22 EP EP13726389.3A patent/EP2852613B1/en active Active
- 2013-05-22 JP JP2015514144A patent/JP6378172B2/ja active Active
-
2014
- 2014-11-16 IL IL235720A patent/IL235720A0/en active IP Right Grant
-
2016
- 2016-09-16 US US15/267,285 patent/US10087230B2/en active Active
-
2018
- 2018-07-26 JP JP2018139890A patent/JP2018196384A/ja active Pending
- 2018-08-29 US US16/115,969 patent/US10407485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525208A5 (enExample) | ||
| Burnett et al. | Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability | |
| JP2015535816A5 (enExample) | ||
| JP2017536825A5 (enExample) | ||
| ES2989669T3 (es) | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana | |
| JP2018121657A5 (enExample) | ||
| JP2014528714A5 (enExample) | ||
| JP2018535647A5 (enExample) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2018536393A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2015529641A5 (enExample) | ||
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| JP2012107017A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| JP2012526542A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2017508475A5 (enExample) | ||
| JP2012100677A5 (enExample) | ||
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 |